<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/416C-5429 " scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-18: Human Lymphocyte Activation (HuLa) Assay for Analysis of Immunosuppressive Properties of Nanomaterials</p><p><b>Protocol Abbreviation:</b> ITA-18</p><p><b>Protocol Version:</b> 3<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/416C-5429 >http://dx.doi.org/10.17917/416C-5429 </a></p><p><b>Protocol File:</b> protocols/20240411_12-52-58-751_NCL_Method_ITA-18.pdf<p><b>File Title:</b> ITA-18</p><p><b>Description:</b></b> Lymphocytes are isolated from human blood, anti-coagulated with Li-heparin, using Ficoll-Paque Premium solution. The blood is obtained from healthy donor volunteers vaccinated with the current season flu vaccine (Fluzone). The isolated cells are incubated with Fluzone in the presence or absence of nanoparticles. After a 72 hour incubation, BrdU is added to cells and the incubation continues for additional 24 hours. At the end of incubation, the cells are fixed and incorporation of BrdU into DNA of proliferating cells is analyzed by ELISA.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>